Didem, A. Y. Et Al. 2012. Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma. 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Geneva, Switzerland), 179.

Didem, A. Y., GÜMÜŞLÜ, S., Parlak, G., Sengul, A., & Gorczynski, R., (2012). Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma . 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.179). Geneva, Switzerland

Didem, Arzu Et Al. "Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma," 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Geneva, Switzerland, 2012

Didem, Arzu Y. Et Al. "Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma." 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Geneva, Switzerland, pp.179, 2012

Didem, A. Y. Et Al. (2012) . "Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma." 31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Geneva, Switzerland, p.179.

@conferencepaper{conferencepaper, author={Arzu Y. Didem Et Al. }, title={Omalizumab affects systemic levels of ceruloplasmin oxidase activity in severe allergic asthma}, congress name={31st Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Geneva}, country={Switzerland}, year={2012}, pages={179} }